HC Wainwright & Co. Reiterates Buy on Iterum Therapeutics, Maintains $6 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Ed Arce reiterates a Buy rating on Iterum Therapeutics (NASDAQ:ITRM) and maintains a $6 price target.

May 14, 2024 | 10:41 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Iterum Therapeutics receives a reiterated Buy rating and a maintained $6 price target from HC Wainwright & Co., indicating a positive outlook from the analyst.
Analyst ratings, especially from reputable firms like HC Wainwright & Co., can significantly influence investor sentiment and stock prices. A reiterated Buy rating and a maintained price target suggest confidence in the company's future performance, potentially leading to increased investor interest and a positive short-term price movement.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100